Genprex, Inc.

DB:2DE0 Stock Report

Market Cap: €4.1m

Genprex Management

Management criteria checks 2/4

Genprex's CEO is John Varner, appointed in Aug 2012, has a tenure of 11.67 years. total yearly compensation is $2.53M, comprised of 22% salary and 78% bonuses, including company stock and options. directly owns 1% of the company’s shares, worth €39.38K. The average tenure of the management team and the board of directors is 3.1 years and 4.1 years respectively.

Key information

John Varner

Chief executive officer

US$2.5m

Total compensation

CEO salary percentage22.0%
CEO tenure11.7yrs
CEO ownership1.0%
Management average tenure3.1yrs
Board average tenure4.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has John Varner's remuneration changed compared to Genprex's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-US$31m

Sep 30 2023n/an/a

-US$31m

Jun 30 2023n/an/a

-US$30m

Mar 31 2023n/an/a

-US$28m

Dec 31 2022US$3mUS$557k

-US$24m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$21m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$2mUS$480k

-US$21m

Sep 30 2021n/an/a

-US$19m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021n/an/a

-US$19m

Dec 31 2020US$2mUS$488k

-US$18m

Sep 30 2020n/an/a

-US$15m

Jun 30 2020n/an/a

-US$15m

Mar 31 2020n/an/a

-US$14m

Dec 31 2019US$659kUS$400k

-US$11m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

-US$11m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$1mUS$338k

-US$12m

Sep 30 2018n/an/a

-US$10m

Jun 30 2018n/an/a

-US$8m

Mar 31 2018n/an/a

-US$3m

Dec 31 2017US$334kUS$300k

-US$3m

Compensation vs Market: John's total compensation ($USD2.53M) is above average for companies of similar size in the German market ($USD401.52K).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

CEO

John Varner (66 yo)

11.7yrs

Tenure

US$2,532,399

Compensation

Mr. John Rodney Varner is a co-founder of Genprex, Inc. He has been the Chief Executive Officer and Chairman of Genprex, Inc. since August 2012 and has been its President since August 10, 2020. He served a...

Leadership Team

NamePositionTenureCompensationOwnership
John Varner
Co-Founder11.7yrsUS$2.53m1.0%
€ 40.7k
Ryan Confer
Chief Financial Officer7.6yrsUS$1.14m0.35%
€ 14.3k
David Schloss
Senior Vice President of Human Resources2.3yrsno datano data
Thomas Gallagher
Senior Vice President of Intellectual Property & Licensing3.6yrsno datano data
Mark Berger
Chief Medical Officer2.6yrsno data0.25%
€ 10.3k
Suzanne Thornton-Jones
Senior Vice President of Regulatory Affairs & Qualityless than a yearno datano data
Jack Roth
Chairman of Scientific & Medical Advisory Boardno datano datano data

3.1yrs

Average Tenure

66yo

Average Age

Experienced Management: 2DE0's management team is considered experienced (3.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Varner
Co-Founder11.7yrsUS$2.53m1.0%
€ 40.7k
Jack Roth
Chairman of Scientific & Medical Advisory Boardno datano datano data
Brent Longnecker
Independent Director4.1yrsUS$150.00k0.046%
€ 1.9k
James E. Rothman
Strategic Advisor to the Board of Directors11.8yrsno datano data
Pasi Antero Janne
Member of Scientific & Medical Advisory Boardno datano datano data
George Peoples
Member of Clinical Advisory Board3.2yrsno datano data
Shu Kam Mok
Member of Scientific & Medical Advisory Boardno datano datano data
George Simon
Member of Scientific & Medical Advisory Boardno datano datano data
William Wilson
Independent Director4.1yrsUS$140.00k0%
€ 0
Jose Antonio Toscano
Independent Director4.1yrsUS$150.00k0%
€ 0
George Gittes
Member of Scientific Advisory Board3.4yrsno datano data
Michael Morse
Member of Clinical Advisory Board3.2yrsno datano data

4.1yrs

Average Tenure

66.5yo

Average Age

Experienced Board: 2DE0's board of directors are considered experienced (4.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/04/30 09:42
End of Day Share Price 2024/02/01 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genprex, Inc. is covered by 1 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners